Fagron Stock

Fagron EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fagron (FAGR.BR) as of Aug 5, 2026 is 183.38 M EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 167.05 M EUR — a change of 9.77% (higher).

EBITDA

183.38 MEUR

YoY

9.77%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fagron is 2026 183.38 M EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fagron was 2025 167.05 M EUR. It decreases by 9.77% higher compared to the previous year.
Access this data via the Eulerpool API

Fagron Stock analysis

What does Fagron do? Fagron NV is an internationally operating company that focuses on the development and production of customized medications for pharmacies and hospitals. The company was founded in 1990 in Rotterdam, Netherlands. The beginnings of Fagron NV were in the Netherlands, where the company was established as Roterodamum Chemie BV. In the late 1990s, the company was converted into a holding company called Arseus NV, which later received the name Fagron. In 2012, Fagron was listed on the Euronext stock exchange in Brussels. Fagron operates globally and has locations in Europe, North America, Latin America, the United Arab Emirates, Asia, and Australia. Fagron's business model is based on the production of specialized medications for individual patient needs. The company offers a wide range of pharmaceutical active ingredients, raw materials, and processing services. There is also the possibility to develop and manufacture customized formulations tailored to the needs of patients. Fagron not only manufactures customized medications but also provides training and support for pharmacies and hospitals. Fagron operates in three main divisions: Specialty Pharma (hospital care), Community Pharma (prescription and non-prescription medications), and Compounding Services (custom formulations). The Specialty Pharma division specializes in medications for use in hospitals. It offers a wide range of products that can be used in the treatment of conditions such as cancer, HIV, and tuberculosis. These medications are manufactured in various dosage forms, such as injections, infusions, and tablets. The Community Pharma division focuses on prescription and non-prescription medications. Both branded and generic medications are offered. These are delivered directly to pharmacies, hospitals, and clinics. The Compounding Services division specializes in the production of customized medications. Fagron works closely with pharmacies and hospitals to meet individual needs. This includes, for example, the manufacture of medications in specific dosages or the combination of several active ingredients in a custom formulation. Fagron offers a wide range of products, including hormones, pain medications, cancer drugs, medications for the treatment of skin diseases, ophthalmic products, and anti-infectives. Pharmaceutical active ingredients and raw materials are also offered. Overall, Fagron is a global leader in the production of customized medications. It has extensive experience and expertise in the manufacturing of pharmaceutical formulations and offers a wide range of products and services. The various divisions of Fagron allow the company to meet the diverse needs of its customers and maintain its position as a leading company in the pharmaceutical industry. Fagron is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fagron stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fagron is 183.38 M EUR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fagron changed from 167.05 M EUR to 183.38 M EUR, representing a 9.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Fagron since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Fagron historically and in real time.

Access this data via the Eulerpool API

Income Statement — Fagron

All Key Metrics — Fagron